Scholarlink

Purpose <p>This study assessed the impact of EUCAST’s Rapid Antimicrobial Susceptibility Testing (RAST) on empirical therapy and its clinical usability in routine bloodstream infection management.</p> Methods <p>This retrospective single-center, observational study compared two four-month periods before and after RAST implementation (Feb–May 2023 vs. Feb–May 2024) at Oldenburg Medical Center. Patients with monomicrobial bloodstream infections due to <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa</i>, or <i>Acinetobacter baumannii</i> were included. Primary outcome: duration of empirical antimicrobial therapy. Secondary outcomes: turnaround time and categorical agreement between RAST with VITEK 2, including major errors (ME) and very major errors (VME). Surrogate-based interpretation was used for ATU results, particularly for piperacillin-tazobactam.</p> Results <p>In total 126 patients were included (66 in 2023, 60 in 2024). After RAST, empirical therapy duration was significantly shorter (40.5&#xa0;h vs. 73.3&#xa0;h, <i>p</i> &lt; 0.001). Median time to RAST result was 15.8&#xa0;h, significantly shorter than by VITEK 2 (33.9&#xa0;h, <i>p</i> &lt; 0.0001), reducing time to first susceptibility result by 9.6&#xa0;h (<i>p</i> &lt; 0.00001). Concordance with VITEK 2 was excellent: 100% for cefotaxime, meropenem, and piperacillin-tazobactam, 96.4% for ceftazidime, 95.2% for ampicillin. ATU results occurred mainly for piperacillin-tazobactam and were partly resolved through surrogate-based interpretation.</p> Conclusion <p>RAST significantly shortened empirical therapy duration and accelerated susceptibility reporting with high agreement to VITEK 2. However, antibiotic-specific uncertainty and incomplete translation of early results into therapeutic action indicate that the clinical impact of RAST depends on structured interpretation and integration into antimicrobial stewardship workflows.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical impact of EUCAST rapid antimicrobial susceptibility testing on empirical therapy in bloodstream infections: a real-world observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月18日

查看全文
  • Lukas Schaffarczyk,
  • Patricia Carla Mayer,
  • Axel Hamprecht,
  • Philipp Thelen

摘要

Purpose

This study assessed the impact of EUCAST’s Rapid Antimicrobial Susceptibility Testing (RAST) on empirical therapy and its clinical usability in routine bloodstream infection management.

Methods

This retrospective single-center, observational study compared two four-month periods before and after RAST implementation (Feb–May 2023 vs. Feb–May 2024) at Oldenburg Medical Center. Patients with monomicrobial bloodstream infections due to Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, or Acinetobacter baumannii were included. Primary outcome: duration of empirical antimicrobial therapy. Secondary outcomes: turnaround time and categorical agreement between RAST with VITEK 2, including major errors (ME) and very major errors (VME). Surrogate-based interpretation was used for ATU results, particularly for piperacillin-tazobactam.

Results

In total 126 patients were included (66 in 2023, 60 in 2024). After RAST, empirical therapy duration was significantly shorter (40.5 h vs. 73.3 h, p < 0.001). Median time to RAST result was 15.8 h, significantly shorter than by VITEK 2 (33.9 h, p < 0.0001), reducing time to first susceptibility result by 9.6 h (p < 0.00001). Concordance with VITEK 2 was excellent: 100% for cefotaxime, meropenem, and piperacillin-tazobactam, 96.4% for ceftazidime, 95.2% for ampicillin. ATU results occurred mainly for piperacillin-tazobactam and were partly resolved through surrogate-based interpretation.

Conclusion

RAST significantly shortened empirical therapy duration and accelerated susceptibility reporting with high agreement to VITEK 2. However, antibiotic-specific uncertainty and incomplete translation of early results into therapeutic action indicate that the clinical impact of RAST depends on structured interpretation and integration into antimicrobial stewardship workflows.